title: A rare type of secondary cancer in a child with acute lymphoblastic leukemia: malignant fibrous histiocytoma.
abstract: Secondary cancers which are related with treatment of childhood acute lymphoblastic leukemia (ALL) is a significant problem with longer term. For development of secondary cancer after treatment, the latency period varies between 5 and 10 years. In this case, a 13 year-old-boy diagnosed as high-risk ALL was treated with chemotherapy and prophylactic cranial radiotherapy at a dose of 1800 cGy. Six years after the end of treatment he developed a 5 × 5 × 4 cm mass at the right temporal region of the cranium. The mass was excised totally with clear surgical margin. Pathology of mass has been diagnosed as malignant fibrous histiocytoma (MFH), recently referred to as an undifferentiated pleomorphic sarcoma (UPS). After treatment of childhood ALL, reported cases of secondary MFH is extremely rare in the literature. Herein we present a case of MFH/UPS that developed as a secondary cancer 6 years after the end of ALL treatment.
authors.affiliation: *Department of Pediatric Oncology, Dr Sami Ulus Obstetrics and Pediatrics Training and Research Hospital †Department of Plastic Surgery, Ankara Numune Training and Research Hospital, Ankara, Turkey.
authors.forename: Sonay
authors.initials: S
authors.lastname: Incesoy Özdemir
authors.forename: Eda
authors.initials: E
authors.lastname: Balkaya
authors.forename: Ayşe C
authors.initials: AC
authors.lastname: Ören
authors.forename: Ceyhun
authors.initials: C
authors.lastname: Bozkurt
authors.forename: Gürses
authors.initials: G
authors.lastname: Sahin
authors.forename: Ramazan E
authors.initials: RE
authors.lastname: Ünlü
authors.forename: Ayşe U
authors.initials: AU
authors.lastname: Ertem
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects; D003131:Combined Modality Therapy; D016371:Cranial Irradiation / Q000009:adverse effects; D051677:Histiocytoma, Malignant Fibrous / Q000209:etiology / Q000473:pathology*; D006801:Humans; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000473:pathology*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000532:radiotherapy
chemical_list: D000970:Antineoplastic Agents